CM Hospitalar (VVEO3) Q2 2024 earnings summary

Executive summary

• Net revenue grew 8.7% year-over-year in 2Q24, driven by high-cost medications and vaccines, but profitability declined due to lower margins and higher expenses.

• Strategic focus on operational efficiency, cost reduction, cash generation, inventory optimization, and deleveraging, with visible improvements in service levels and working capital.

• Expansion and centralization of distribution centers in Cajamar and Brasília to enhance logistics and order processing capacity.

• Board strengthened with new independent members and creation of a Strategy Committee to support governance and execution.

• Despite challenges, management expects profitability and robust cash generation to recover by year-end.

Financial highlights

• 2Q24 net revenue: R$2,753.5M (+8.7% YoY); 1H24: R$5,711.7M (+7.1% YoY).

• 2Q24 gross profit: R$397.3M (-12.6% YoY); gross margin: 14.4% (-3.5pp YoY).

• 2Q24 adjusted EBITDA: R$171.3M (-31.8% YoY); margin: 6.2% (-3.7pp YoY).

• 2Q24 net loss: R$87.7M; adjusted net loss: R$5.2M.

• 2Q24 free cash flow: R$313.8M (+34.8% YoY); 1H24: R$142.0M vs. -R$491.6M in 1H23.

Outlook and guidance

• Management expects further improvements in inventory, service levels, and expense reduction in 2H24, with profitability and cash generation expected to recover by year-end.

• Strategic projects target sustainable growth, margin recovery, and further deleveraging, with focus on sales with higher ROIC and discontinuing low-return operations.

• Centralization and automation initiatives to improve service and cost competitiveness from 3Q24 and 1Q25.